This company listing is no longer active
IntelGenx Technologies (0IL) Stock Overview
A drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
0IL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
IntelGenx Technologies Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.14 |
| 52 Week High | US$0.21 |
| 52 Week Low | US$0.061 |
| Beta | 2.6 |
| 1 Month Change | 0% |
| 3 Month Change | 20.17% |
| 1 Year Change | 16.26% |
| 3 Year Change | -57.82% |
| 5 Year Change | -61.35% |
| Change since IPO | -77.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0IL | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 6.4% | 1.3% |
| 1Y | 16.3% | -7.7% | 15.8% |
Return vs Industry: 0IL exceeded the German Pharmaceuticals industry which returned -18.8% over the past year.
Return vs Market: 0IL exceeded the German Market which returned 0.4% over the past year.
Price Volatility
| 0IL volatility | |
|---|---|
| 0IL Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0IL's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0IL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Dwight Gorham | www.intelgenx.com |
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression.
IntelGenx Technologies Corp. Fundamentals Summary
| 0IL fundamental statistics | |
|---|---|
| Market cap | €26.46m |
| Earnings (TTM) | -€10.01m |
| Revenue (TTM) | €953.47k |
Is 0IL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0IL income statement (TTM) | |
|---|---|
| Revenue | US$1.05m |
| Cost of Revenue | US$1.75m |
| Gross Profit | -US$694.00k |
| Other Expenses | US$10.34m |
| Earnings | -US$11.03m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.063 |
| Gross Margin | -66.03% |
| Net Profit Margin | -1,049.48% |
| Debt/Equity Ratio | -103.7% |
How did 0IL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/14 10:16 |
| End of Day Share Price | 2024/05/17 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IntelGenx Technologies Corp. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Haynor | Aegis Capital Corporation |
| Christian Orquera | First Berlin Equity Research GmbH |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |